Drug    DrugBank | All Description Patterns💬 Info on mouse-over

No.	Drug (Description in trials)	DrugBank	KEGG DRUG	KEGG GENES	KEGG PATHWAY On map, Yellow: Drug target genes	Disease ID
1	Biologic dmard	-	-	-	-	[2] 46, 271 💬
2	Biological dmards	-	-	-	-	[1] 86 💬
3	Classic dmards treatment group	-	-	-	-	[1] 46 💬
4	Co-medication: synthetic dmards	-	-	-	-	[1] 46 💬
5	Conventional dmard combination	-	-	-	-	[1] 46 💬
6	Conventional dmards	-	-	-	-	[1] 46 💬
7	Conventional synthetic dmard	-	-	-	-	[1] 46 💬
8	Disease-modifying antirheumatic drugs (dmards)	-	-	-	-	[1] 46 💬
9	Dmard	-	-	-	-	[1] 46 💬
10	Dmard cessation	-	-	-	-	[1] 46 💬
11	Dmard maintenance	-	-	-	-	[1] 46 💬
12	Dmard therapy	-	-	-	-	[1] 46 💬
13	Dmards	-	-	-	-	[2] 46, 271 💬
14	Dmards (disease-modifying antirheumatic drugs)	-	-	-	-	[1] 46 💬
15	Dmards (methotrexate	Methotrexate	[2] D00142, D02115 💬	[2] DHFR, DHFR2 💬	[5] Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate	[1] 46 💬
16	Dmards or biologics	-	-	-	-	[1] 46 💬
17	Etanercept, other biologics, disease-modifying antirheumatic drugs (dmards), etc	Etanercept	[1] D00742 💬	[2] LTA, TNF 💬	[65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway	[1] 46 💬
18	Huc-msc + dmards	-	-	-	-	[1] 46 💬
19	Non-biologic disease modifying anti-rheumatic drug (dmard)	-	-	-	-	[1] 46 💬
20	Non-biologic dmards	-	-	-	-	[2] 46, 86 💬
21	Non-biological dmard's	-	-	-	-	[1] 46 💬
22	Non-biological dmards	-	-	-	-	[1] 46 💬
23	Nonbiologic dmards of investigator's choice	-	-	-	-	[1] 46 💬
24	Other dmards	-	-	-	-	[1] 46 💬
25	Other: group 2 (dmards treated group)	-	-	-	-	[1] 46 💬
26	Patient treated with dmard	-	-	-	-	[1] 46 💬
27	Permitted dmards	-	-	-	-	[1] 46 💬
28	Phase 1: conventiaonal dmard	-	-	-	-	[1] 46 💬
29	Rheumatoid arthritis with disease-modifying drugs (dmards)	-	-	-	-	[1] 46 💬
30	Standard dmards (disease modifying anti rheumatic drugs)	-	-	-	-	[1] 46 💬
31	Synthetic dmard(s)	-	-	-	-	[1] 46 💬
32	Therapy with disease-modifying anti rheumatic drugs (dmard)	-	-	-	-	[1] 46 💬
33	Tnf-a antagonists, non-tnfs, dmard non-biologics	-	-	-	-	[2] 46, 271 💬
34	Uc-msc+dmards	-	-	-	-	[1] 46 💬

Back to top